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Mania with psychotic features is one of the common presenting clusters of psychiatric symptoms in HIV-infected patients. 
Commonly, patients with HIV-associated mania receive antiretroviral treatment, mood stabilisers and antipsychotics. This case 
of Stevens-Johnson syndrome highlights the dilemmas and complications that may arise when prescribing multiple medications 
in HIV-associated psychiatric disorders. 
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HIV enters the central nervous system early 
in the course of HIV infection and causes a 
range of neuropsychiatric complications, inclu-
ding HIV encephalopathy, depression, ma-
nia, cognitive disorders and frank demen tia. [1] 
Mania is one of the most common psychiatric presentations in 
HIV-infected patients and requires antiretroviral therapy (ART), 
mood stabilisers and antipsychotics to increase patient quality of 
life and decrease mortality.[1-3] ART may also protect from further 
cognitive deterioration and preserve functionality.[1]
The link between systemic hypersensitivity reactions and 
nevirapine has been well documented.[4] Case reports have 
also demonstrated adverse cutaneous reactions associated 
with the use of sodium valproate and risperidone.[5,6] This 
report describes the case of an HIV-seropositive patient who 
presented with mania for the first time and was treated with 
nevirapine, sodium valproate and risperidone. He developed 
Stevens-Johnson syndrome (SJS), which progressed to toxic 
epidermal necrolysis (TEN) and death over a period of 26 days.
Background
SJS/TEN comprises cutaneous adverse reactions ranging from 
mild erythematous macules to extensive epidermal detachment 
and mucous membrane erosion. The international classification 
of SJS/TEN is based on the body surface area (BSA) involved: 
SJS involves <10% of BSA; TEN involves >30%; and there is an 
overlap in definitions with involvement of 10 - 30%.[7]
Mortality associated with SJS, SJS/TEN and TEN is 10%, 
30% and >50%, respectively.[7] Common causes of death include 
septic shock, hypovolaemic shock, acute renal failure and 
fulminant hepatitis.[8] The most common drugs implicated 
are sulphonamide antibiotics (38%) and nevirapine (20%). [9] 
An immunological response involving CD8+ T lymphocytes is 
the most likely explanation for the pathogenesis of SJS/TEN.[10] 
Other potential factors are the causative drug’s inherent 
properties or chemical structure, patient factors such as HIV 
status and CD4+ count, ethnic background, age and gender. 
Affected individuals with SJS/TEN are genetically predisposed 
to developing severe cutaneous reactions based on the major 
histocompatibility complex molecules on their leukocyte cell 
surface.[10] A study in Taiwan showed that 100% of Han Chinese 
patients who developed SJS in response to carbamazepine 
had an HLA B*1502 allele.[11] Comorbidity of SJS/TEN and 
HIV is posing a challenge in sub-Saharan Africa due to the 
high prevalence of HIV. In this setting, sulphonamides and 
nevirapine are the most commonly implicated drugs. 
Case report
A 28-year-old man was referred to the mental health unit (MHU) 
with a 3-week history of manic symptoms, presenting for the 
first time. He was irritable, displayed pressure of speech, and 
had decreased need for sleep, increased drive, hyper-religiosity, 
impulsivity (reckless spending of money) and auditory hallucin-
ations. He tested positive for HIV and syphilis (rapid plasma rea-
gin (RPR) titre of 1:8). His CD4+ count was 334 cells/µl and he 
was not on ART. Cerebrospinal fluid analysis was negative for 
neurosyphilis. Chest X-ray and GeneXpert on sputum excluded 
tuberculosis. Treatment initiated on admission was 3 mg risperi-
done daily, 500 mg sodium valproate twice daily and penicillin. 
On day 3 after admission, he was prescribed 300 mg zidovudine 
twice daily, 150 mg lamivudine twice daily and 200 mg nevirapine 
daily. The nevirapine dose was to be doubled to 200 mg twice 
daily after 14 days. His psychiatric symptoms responded well 
to treatment and he was discharged on day 8 post admission. 
On day 7 he had complained of a mild rash on his hands and 
nevirapine was suspected as the cause. ART was continued, and 
4 mg chlorphenamine three times daily and hydrocortisone 1% 
cream were prescribed. Review at follow-up on day 3 and day 6 
post discharge revealed that the rash had settled and he remained 
physically and mentally well. The nevirapine dose was increased, 
as per treatment plan, on day 10 post discharge. He presented 

















a severe SJS/TEN reaction (Fig. 1), which had developed on day 10 post 
discharge, coinciding with the increase in nevirapine. He had continued 
his treatment and had waited for his next follow-up appointment before 
reporting the rash. He was re-admitted to the intensive care unit where 
his condition deteriorated, with death occurring on day 6 of his second 
admission. Death was thought to be related to infection and renal failure.
The patient was initiated on ART while admitted to the MHU, which 
is common in our setting and other parts of South Africa (SA) as ART 
initiation may help to ameliorate HIV-associated neuropsychiatric 
symptoms and potentially improve cognitive function in particular. In 
this case, the choice of ART regimen was influenced by a number of 
factors, including the safety profile of both efavirenz and nevirapine, 
the risk of ART-induced neuropsychiatric side-effects (more commonly 
seen with efavirenz), the patient’s wishes, informed consent given for 
further management of his condition, the applicable World Health 
Organization staging and the latest SA National Department of Health 
ART guidelines.[12] The fatal outcome raises questions regarding the 
initiation of ART in patients with similar presentations and the role 
played by the following factors in the development and clinical outcome 
of SJS/TEN: HIV infection, CD4+ count, causative drug, age, gender 
and use of steroids during the acute stages. This case emphasises the 
need for further research into these factors to aid clinicians in decision-
making when it comes to safe options for HIV-associated mania.
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Fig. 1. Severe SJS/TEN affecting trunk and upper limbs. (SJS = Stevens-
Johnson syndrome; TEN = toxic epidermal necrolysis.)
